Home > Insider Trading > Filing (0001213900-24-021961)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1788028	Jasper Therapeutics Inc.	JSPR	Biological Products, (No Disgnostic Substances) (2836)	842984849

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1882877	Singh Jeetinder Mahal	C/O Jasper Therapeutics, Inc. 2200 Bridge Pkwy, Suite 102 Redwood City CA 94065	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Voting Common Stock	Acquisiton	2024-03-12	900	$7.10	25,909	No	4	M	Direct
Voting Common Stock	Disposition	2024-03-12	900	$26.44	25,009	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Voting Common Stock	Stock Option (right to buy)	Acquisiton	2024-03-12	900	$0.00	900	$7.10

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
16,472		2030-05-31	No	4	M	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.
Effective on January 4, 2024, the Issuer conducted a reverse stock split of its voting common stock at a ratio of 1-for-10 (the "Reverse Split"). The number of shares reported herein reflects the number of shares after the Reverse Split.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.14 to $26.79, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
The exercise price of the option and number of shares subject to the option were adjusted as a result of the Reverse Split, and numbers reported herein reflect the exercise price and number of shares subject to the option after the Reverse Split.
25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter.